ASH Annual Meeting and Exposition | Conference

Treatment Selection Could Be Informed by Cost and Time Spent on Managing Toxicity in CLL

December 13th 2021

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment

December 13th 2021

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Achieves 77% uMRD Rate in CLL

December 13th 2021

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL

December 13th 2021

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

Cilta-cel Shows Greater Clinical Benefit Than SOC in Triple-Class Relapsed/Refractory Myeloma

December 12th 2021

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

December 12th 2021

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

December 12th 2021

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Daratumumab/IRd Quadruplet Is Safe and Effective as Induction, Consolidation for Standard-Risk Myeloma

December 12th 2021

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.

IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis

December 12th 2021

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma

December 12th 2021

Minimal residual disease, assessed through next-generation sequencing was found to inform treatment selection and duration with daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant in patients with newly diagnosed multiple myeloma.

Axi-Cel Improves QoL in Second-Line Treatment of LBCL

December 12th 2021

Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.

Weekly Selinexor/Bortezomib/Dexamethasone Combo Demonstrates Favorable Efficacy and Safety in High-Risk Multiple Myeloma

December 12th 2021

Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.

Chemotherapy Plus Eryaspase Demonstrates Efficacy in ALL With Risk for Hypersensitivity Reactions

December 12th 2021

The addition of eryaspase to chemotherapy demonstrated biological efficacy and tolerability in patients with acute lymphoblastic leukemia who are at risk of developing hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Tisagenlecleucel Continues to Show Favorable Real-World Efficacy and Safety in R/R B-Cell Non-Hodgkin Lymphomas

December 12th 2021

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Asciminib Induces Deeper and Prolonged Molecular Responses in Chronic-Phase CML

December 12th 2021

Asciminib demonstrated a consistent improvement in major molecular response rate and depth of response vs bosutinib in patients with chronic-phase chronic myeloid leukemia without any new or worsening adverse effects.

Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

December 12th 2021

Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma.

Acalabrutinib Provides Long-Term Survival Benefits Vs. Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 12th 2021

Treatment with acalabrutinib for relapsed/refractory chronic lymphocytic leukemia was effective out to 3 years and demonstrated a progression-free survival benefit over standard of care, according to 3-year follow-up of the ASCEND study.

Frontline and Continuous Treatment With Ibrutinib Plus Rituximab Improves Quality of Life in Patients With CLL

December 12th 2021

Quality of life improved in patients with chronic lymphocytic leukemia when treated in the frontline setting with ibrutinib-rituximab and with fludarabine, cyclophosphamide, and rituximab. Improved quality of life was also maintained during continuous therapy with ibrutinib and did not decline over time.

Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes

December 12th 2021

Real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with tisagenlecleucel demonstrated similar efficacy outcomes and a more favorable safety profile compared with the ELIANA trial.

Selinexor Plus D-Vd Shows Promising Results and Safety in Patients With Relapsed or Refractory Multiple Myeloma

December 12th 2021

Selinexor in combination with daratumumab, bortezomib and dexamethasone demonstrated a manageable safety profile and encouraging efficacy in patients with late- and early-relapsed multiple myeloma.